Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838900 | 0.92 | HPGD (0.61) | HPGDALDH1A1HRH3MEN1MAPT | |
| SCHEMBL13838915 | 0.88 | HRH3 (0.46) | HPGDALDH1A1HRH3MEN1MAPT | |
| SCHEMBL26027797 | 0.85 | KMT2A (0.54) | HRH3MEN1MAPTKMT2ARAB9A | |
| SCHEMBL23972318 | 0.85 | HRH3 (0.52) | HPGDALDH1A1HRH3MEN1MAPT | |
| SCHEMBL3809631 | 0.83 | HPGD (0.60) | HPGDALDH1A1HRH3MEN1MAPT | |
| SCHEMBL26027577 | 0.82 | HRH3 (0.53) | HPGDALDH1A1HRH3MEN1MAPT | |
| SCHEMBL3132249 | 0.82 | SMN1; SMN2 (0.54) | HPGDALDH1A1HRH3MAPTRAB9A | |
| SCHEMBL13838919 | 0.82 | HRH3 (0.41) | HPGDALDH1A1HRH3MEN1MAPT | |
| SCHEMBL3809234 | 0.82 | HSD11B1 (0.51) | HPGDHRH3 | |
| SCHEMBL3813715 | 0.81 | HPGD (0.54) | HPGDALDH1A1HRH3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD11B2, HSD3B1 | HPGD 28/4885ALDH1A1 220/4885HRH3 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.